HRP20201600T1 - Anti-pd-1 antitijelo i njegova uporaba - Google Patents
Anti-pd-1 antitijelo i njegova uporaba Download PDFInfo
- Publication number
- HRP20201600T1 HRP20201600T1 HRP20201600TT HRP20201600T HRP20201600T1 HR P20201600 T1 HRP20201600 T1 HR P20201600T1 HR P20201600T T HRP20201600T T HR P20201600TT HR P20201600 T HRP20201600 T HR P20201600T HR P20201600 T1 HRP20201600 T1 HR P20201600T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- antigen
- binding fragment
- conditions
- seq
- Prior art date
Links
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Claims (8)
1. Anti-PD-1 antitijelo ili njegov fragment koji veže antigen sadrži varijabilnu regiju teškog lanca koja se sastoji od SEQ ID NO: 33 i varijabilnu regiju lakog lanca koja se sastoji od SEQ ID NO: 34.
2. Izolirana molekula nukleinske kiseline, koja kodira antitijelo ili njegov fragment koji veže antigen prema zahtjevu 1.
3. Ekspresijski vektor, koji sadrži molekulu nukleinske kiseline prema zahtjevu 2.
4. Stanica domaćina, koja sadrži ekspresijski vektor prema zahtjevu 3.
5. Postupak za proizvodnju anti-PD-1 antitijela ili njegovog fragmenta koji veže antigen prema zahtjevu 1, naznačen time što postupak obuhvaća: uzgoj stanice domaćina prema zahtjevu 4 pod uvjetima koji omogućavaju proizvodnju antitijela ili njegovog fragmenta koji veže antigen, i obnavljanje tako proizvedenog antitijela ili njegovog fragmenta koji veže antigen.
6. Imunokonjugat, koji sadrži antitijelo ili njegov fragment koji veže antigen, prema zahtjevu 1 spojen s terapijskim sredstvom, pri čemu je terapijsko sredstvo toksin, radioizotop, lijek ili citotoksično sredstvo.
7. Farmaceutski pripravak, koji sadrži antitijelo ili njegov fragment koji veže antigen prema zahtjevu 1 i farmaceutski nosač.
8. Antitijelo ili njegov fragment koji veže antigen prema zahtjevu 1 ili njegov farmaceutski pripravak koji sadrži antitijelo ili njegov fragment koji veže antigen, za uporabu u postupku prevencije ili liječenja bolesti ili stanja uklanjanjem, inhibiranjem ili smanjenjem aktivnosti PD-1 , pri čemu su bolesti ili stanja karcinomi.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310258289.2A CN104250302B (zh) | 2013-06-26 | 2013-06-26 | 抗pd‑1抗体及其应用 |
EP14818708.1A EP3026062B1 (en) | 2013-06-26 | 2014-02-26 | Anti-pd-1 antibody and use thereof |
PCT/CN2014/072574 WO2014206107A1 (zh) | 2013-06-26 | 2014-02-26 | 抗pd-1抗体及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20201600T1 true HRP20201600T1 (hr) | 2021-03-05 |
Family
ID=52140971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20201600TT HRP20201600T1 (hr) | 2013-06-26 | 2020-10-07 | Anti-pd-1 antitijelo i njegova uporaba |
Country Status (16)
Country | Link |
---|---|
US (3) | US10066013B2 (hr) |
EP (2) | EP3026062B1 (hr) |
JP (1) | JP6681327B2 (hr) |
CN (1) | CN104250302B (hr) |
BR (1) | BR112015031883A2 (hr) |
DK (1) | DK3026062T3 (hr) |
ES (1) | ES2822927T3 (hr) |
HR (1) | HRP20201600T1 (hr) |
HU (1) | HUE052487T2 (hr) |
MY (1) | MY176822A (hr) |
PH (1) | PH12015502819A1 (hr) |
PL (1) | PL3026062T3 (hr) |
PT (1) | PT3026062T (hr) |
RU (1) | RU2663795C2 (hr) |
SI (1) | SI3026062T1 (hr) |
WO (1) | WO2014206107A1 (hr) |
Families Citing this family (222)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US10144778B2 (en) | 2014-03-12 | 2018-12-04 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US9982052B2 (en) | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
ES2847311T3 (es) | 2014-08-05 | 2021-08-02 | MabQuest SA | Reactivos inmunológicos que se unen a PD-1 |
EP3916017A1 (en) | 2014-12-22 | 2021-12-01 | PD-1 Acquisition Group, LLC | Anti-pd-1 antibodies |
US11639385B2 (en) | 2014-12-22 | 2023-05-02 | Pd-1 Acquisition Group, Llc | Anti-PD-1 antibodies |
CA2978942A1 (en) * | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
CN105061597B (zh) * | 2015-06-09 | 2016-04-27 | 北京东方百泰生物科技有限公司 | 一种抗pd-1的单克隆抗体及其获得方法 |
EP3322732A2 (en) | 2015-07-13 | 2018-05-23 | Cytomx Therapeutics Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
CN116059219A (zh) | 2015-07-16 | 2023-05-05 | 比奥克斯塞尔医疗股份有限公司 | 一种使用免疫调节治疗癌症的新颖方法 |
CN106699888B (zh) * | 2015-07-28 | 2020-11-06 | 上海昀怡健康科技发展有限公司 | 一种pd-1抗体及其制备方法和应用 |
CN106390115A (zh) * | 2015-07-29 | 2017-02-15 | 上海君实生物医药科技股份有限公司 | 一种人源化单克隆抗体的稳定制剂 |
WO2017024465A1 (en) * | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
CN106432494B9 (zh) * | 2015-08-11 | 2022-02-15 | 广州誉衡生物科技有限公司 | 新型抗-pd-1抗体 |
SG10201914109VA (en) | 2015-08-11 | 2020-02-27 | Wuxi Biologics Cayman Inc | Novel anti-pd-1 antibodies |
MA48579A (fr) | 2015-09-01 | 2020-03-18 | Agenus Inc | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci |
JP6156604B1 (ja) * | 2015-09-03 | 2017-07-05 | 小野薬品工業株式会社 | Allergin−1アンタゴニストによるがん免疫増強剤 |
CA3000638C (en) | 2015-09-29 | 2024-02-27 | Asia Biotech Pte. Ltd. | Pd-1 antibodies and uses thereof |
EA201890790A1 (ru) | 2015-09-29 | 2018-10-31 | Селджин Корпорейшн | Связывающие pd-1 белки и способы их применения |
SI3368572T1 (sl) | 2015-10-02 | 2022-10-28 | Symphogen A/S | Protitelesa proti PD-1 in sestavki |
US11207393B2 (en) * | 2015-10-16 | 2021-12-28 | President And Fellows Of Harvard College | Regulatory T cell PD-1 modulation for regulating T cell effector immune responses |
BR112018008891A8 (pt) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos |
CN106699889A (zh) * | 2015-11-18 | 2017-05-24 | 礼进生物医药科技(上海)有限公司 | 抗pd-1抗体及其治疗用途 |
CN105566496B (zh) * | 2015-11-26 | 2019-04-02 | 大庆东竺明生物技术有限公司 | 阻断人程序性死亡因子1(pd-1)功能的单克隆抗体及其编码基因和应用 |
US11214617B2 (en) | 2016-01-22 | 2022-01-04 | MabQuest SA | Immunological reagents |
US10294299B2 (en) | 2016-01-22 | 2019-05-21 | MabQuest SA | Immunological reagents |
WO2017132827A1 (en) * | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
MX2017016851A (es) * | 2016-03-04 | 2018-04-30 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Anticuerpo para el ligando del factor 1 de muerte celular programada (pdl-1), composicion farmaceutica del mismo y uso de los mismos. |
CN105950715B (zh) * | 2016-04-27 | 2019-04-26 | 深圳市第三人民医院 | 检测δ42pd1的方法、引物及试剂盒 |
CN105968200B (zh) | 2016-05-20 | 2019-03-15 | 瑞阳(苏州)生物科技有限公司 | 抗人pd-l1人源化单克隆抗体及其应用 |
CN106008714B (zh) | 2016-05-24 | 2019-03-15 | 瑞阳(苏州)生物科技有限公司 | 抗人pd-1人源化单克隆抗体及其应用 |
SG11201810023QA (en) | 2016-05-27 | 2018-12-28 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof |
CN106085955B (zh) * | 2016-06-08 | 2019-09-10 | 中南大学 | 一种同时分离外周血t、b淋巴细胞的方法 |
JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗pd-l1およびil-2サイトカイン |
CN106046162B (zh) * | 2016-06-21 | 2019-04-02 | 大庆东竺明生物技术有限公司 | 抗人程序性死亡因子1(pd-1)单克隆抗体的制备及应用 |
WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
CN106967172B (zh) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
CN106977602B (zh) * | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
CA3036913C (en) | 2016-09-14 | 2023-05-16 | Beijing Hanmi Pharm. Co., Ltd. | Antibody specifically binding to il-17a and functional fragment thereof |
MX2019002969A (es) * | 2016-09-14 | 2019-09-18 | Beijing hanmi pharm co ltd | Anticuerpo que se une especificamente a pd-1 y fragmento funcional del mismo. |
MX2019002946A (es) * | 2016-09-14 | 2019-09-26 | Abbvie Biotherapeutics Inc | Anticuerpos anti-pd-1 y sus usos. |
WO2018053405A1 (en) | 2016-09-19 | 2018-03-22 | Celgene Corporation | Methods of treating immune disorders using pd-1 binding proteins |
US10766958B2 (en) | 2016-09-19 | 2020-09-08 | Celgene Corporation | Methods of treating vitiligo using PD-1 binding antibodies |
CN117586403A (zh) | 2016-10-11 | 2024-02-23 | 艾吉纳斯公司 | 抗lag-3抗体及其使用方法 |
WO2018081621A1 (en) | 2016-10-28 | 2018-05-03 | Bristol-Myers Squibb Company | Methods of treating urothelial carcinoma using an anti-pd-1 antibody |
BR112019008223A2 (pt) | 2016-11-03 | 2019-07-16 | Bristol-Myers Squibb Company | anticorpos anti-ctla-4 ativáveis e usos dos mesmos |
MA50948A (fr) | 2016-12-07 | 2020-10-14 | Agenus Inc | Anticorps et procédés d'utilisation de ceux-ci |
EA201991383A1 (ru) | 2016-12-07 | 2019-12-30 | Эйдженус Инк. | Антитела против ctla-4 и способы их применения |
WO2018119474A2 (en) * | 2016-12-23 | 2018-06-28 | Remd Biotherapeutics, Inc. | Immunotherapy using antibodies that bind programmed death 1 (pd-1) |
CN110198954A (zh) | 2017-01-13 | 2019-09-03 | 艾吉纳斯公司 | 与ny-eso-1结合的t细胞受体和其使用方法 |
BR112019013238A2 (pt) * | 2017-01-20 | 2020-02-11 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Anticorpos anti-pd-1 e usos dos mesmos |
CN108341871A (zh) * | 2017-01-24 | 2018-07-31 | 三生国健药业(上海)股份有限公司 | 抗pd-1单克隆抗体及其制备方法和应用 |
AU2018229278A1 (en) | 2017-02-28 | 2019-10-17 | Sanofi | Therapeutic RNA |
US20210101980A1 (en) | 2017-03-31 | 2021-04-08 | Bristol-Myers Squibb Company | Methods of treating tumor |
CA3185303A1 (en) | 2017-04-05 | 2018-10-11 | Symphogen A/S | Combination therapies targeting pd-a, tim-3, and lag-3 |
TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
EP3609921A2 (en) | 2017-04-13 | 2020-02-19 | Agenus Inc. | Anti-cd137 antibodies and methods of use thereof |
CN106939049B (zh) | 2017-04-20 | 2019-10-01 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用 |
EP3618863B1 (en) | 2017-05-01 | 2023-07-26 | Agenus Inc. | Anti-tigit antibodies and methods of use thereof |
BR112019021847A2 (pt) | 2017-05-30 | 2020-06-02 | Bristol-Myers Squibb Company | Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1 |
EP3630842A2 (en) | 2017-05-30 | 2020-04-08 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
SI3631454T1 (sl) | 2017-05-30 | 2023-12-29 | Bristol-Myers Squibb Company | Zdravljenje lag-3 pozitivnih tumorjev |
US11566073B2 (en) | 2017-06-01 | 2023-01-31 | Bristol-Myers Squibb Company | Methods of treating a tumor using an anti-PD-1 antibody |
WO2018222949A1 (en) | 2017-06-01 | 2018-12-06 | Cytomx Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | ANTI-CD137 MOLECULES AND THEIR USE |
JP7387585B2 (ja) | 2017-09-04 | 2023-11-28 | アジェナス インコーポレイテッド | 混合系統白血病(mll)特異的ホスホペプチドに結合するt細胞受容体およびその使用方法 |
CN107446048B (zh) * | 2017-09-13 | 2021-03-30 | 北京韩美药品有限公司 | 一种能够特异性地结合pd-1的抗体及其功能片段 |
TW201920282A (zh) * | 2017-09-29 | 2019-06-01 | 中國大陸商上海藥明生物技術有限公司 | 抗egfr和pd-1的雙特異性抗體 |
EP3694884A1 (en) | 2017-10-15 | 2020-08-19 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2019090330A1 (en) | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Methods of treating a tumor |
JP2021502066A (ja) | 2017-11-06 | 2021-01-28 | ジェネンテック, インコーポレイテッド | がんの診断及び療法 |
WO2019096136A1 (zh) * | 2017-11-14 | 2019-05-23 | 拜西欧斯(北京)生物技术有限公司 | 抗pd-1抗体及其制备方法和应用 |
WO2019109238A1 (en) | 2017-12-05 | 2019-06-13 | Lyvgen Biopharma Co., Ltd. | Anti-cd137 antibodies and uses thereof |
EP3740507A4 (en) | 2018-01-15 | 2022-08-24 | Nanjing Legend Biotech Co., Ltd. | SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1 |
US20210363242A1 (en) | 2018-01-16 | 2021-11-25 | Bristol-Myers Squibb Company | Methods of treating cancer with antibodies against tim3 |
AU2019209435A1 (en) | 2018-01-22 | 2020-09-17 | Bristol-Myers Squibb Company | Compositions and methods of treating cancer |
AU2019210332A1 (en) | 2018-01-22 | 2020-09-10 | Pascal Biosciences Inc. | Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells |
WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
CN110269865A (zh) * | 2018-03-16 | 2019-09-24 | 山东大学 | 黑根霉胞外多糖在制备治疗诱发性结肠癌药物中的应用 |
SG11202008802QA (en) * | 2018-03-22 | 2020-10-29 | Keires Ag | Antagonistic pd-1, pd-l1 and lag-3 binding proteins |
PE20210665A1 (es) | 2018-03-23 | 2021-03-31 | Bristol Myers Squibb Co | Anticuerpos contra mica y/o micb y sus usos |
CN111971306A (zh) | 2018-03-30 | 2020-11-20 | 百时美施贵宝公司 | ***的方法 |
JP2021520201A (ja) | 2018-04-04 | 2021-08-19 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 抗cd27抗体およびその使用 |
CN111821434A (zh) * | 2019-04-17 | 2020-10-27 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在制备治疗实体瘤的药物中的用途 |
WO2019201169A1 (en) * | 2018-04-15 | 2019-10-24 | Salubris (Chengdu) Biotech Co., Ltd | Antibodies binding pd-1 and uses thereof |
AU2019261451A1 (en) | 2018-04-26 | 2020-12-03 | Agenus Inc. | Heat shock protein-binding peptide compositions and methods of use thereof |
CN108840932B (zh) * | 2018-04-28 | 2022-03-29 | 中国科学院微生物研究所 | 一种pd-1特异性抗体及其抗肿瘤应用 |
IL307925A (en) | 2018-05-07 | 2023-12-01 | Genmab As | Combination of an antibody against 1-PD and conjugation of a drug with an antibody against TF for use in the treatment of cancer |
WO2019219064A1 (en) * | 2018-05-17 | 2019-11-21 | Nanjing Leads Biolabs Co.Ltd | Antibody binding pd-1 and use thereof |
TW202017569A (zh) | 2018-05-31 | 2020-05-16 | 美商佩樂敦治療公司 | 用於抑制cd73之組合物及方法 |
EP3810653A1 (en) | 2018-06-23 | 2021-04-28 | F. Hoffmann-La Roche AG | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
AU2019305637A1 (en) | 2018-07-18 | 2021-03-11 | Genentech, Inc. | Methods of treating lung cancer with a PD-1 axis binding antagonist, an antimetabolite, and a platinum agent |
CN109160949B (zh) * | 2018-07-23 | 2021-05-14 | 中国医学科学院血液病医院(血液学研究所) | 一种鼠抗人pd-1单克隆抗体及应用 |
CN112739371A (zh) | 2018-07-26 | 2021-04-30 | 百时美施贵宝公司 | 用于治疗癌症的lag-3组合疗法 |
CA3107596A1 (en) | 2018-08-23 | 2020-02-27 | Seagen Inc. | Anti-tigit antibodies |
EP3847154A1 (en) | 2018-09-03 | 2021-07-14 | F. Hoffmann-La Roche AG | Carboxamide and sulfonamide derivatives useful as tead modulators |
CN112972675A (zh) * | 2018-09-07 | 2021-06-18 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在***中的用途 |
CN113544144A (zh) | 2018-09-19 | 2021-10-22 | 高山免疫科学股份有限公司 | 变体cd80融合蛋白和相关构建体的方法和用途 |
US20210395392A1 (en) | 2018-10-09 | 2021-12-23 | Bristol-Myers Squibb Company | Anti-mertk antibodies for treating cancer |
SG11202102864XA (en) | 2018-10-19 | 2021-05-28 | Bristol Myers Squibb Co | Combination therapy for melanoma |
JP2022505647A (ja) | 2018-10-23 | 2022-01-14 | ブリストル-マイヤーズ スクイブ カンパニー | 腫瘍の処置方法 |
JP6988769B2 (ja) * | 2018-11-08 | 2022-01-05 | 株式会社デンソー | 開閉体制御装置及びモータ |
AU2019380307A1 (en) | 2018-11-16 | 2021-07-01 | Bristol-Myers Squibb Company | Anti-NKG2A antibodies and uses thereof |
EP3666905A1 (en) | 2018-12-11 | 2020-06-17 | Sanofi | E. coli positive for pks island as marker of positive response to anti-pd1 therapy in colorectal cancer |
AU2019396360A1 (en) | 2018-12-11 | 2021-05-27 | Theravance Biopharma R&D Ip, Llc | Naphthyridine and quinoline derivatives useful as ALK5 inhibitors |
CN111303283A (zh) * | 2018-12-12 | 2020-06-19 | 上海君实生物医药科技股份有限公司 | 抗il-17a抗体及其应用 |
CN111423510B (zh) | 2019-01-10 | 2024-02-06 | 迈威(上海)生物科技股份有限公司 | 重组抗人pd-1抗体及其应用 |
AU2020208193A1 (en) | 2019-01-14 | 2021-07-29 | BioNTech SE | Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine |
AU2020210614A1 (en) | 2019-01-21 | 2021-08-26 | Sanofi | Therapeutic RNA and anti-PD1 antibodies for advanced stage solid tumor cancers |
CN112969716B (zh) * | 2019-02-03 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | 抗pd-1抗体、其抗原结合片段及医药用途 |
CN113891748A (zh) | 2019-03-28 | 2022-01-04 | 百时美施贵宝公司 | ***的方法 |
KR20210146348A (ko) | 2019-03-28 | 2021-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
CA3134522A1 (en) | 2019-04-19 | 2020-10-22 | Genentech, Inc. | Anti-mertk antibodies and their methods of use |
EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
EP3966252A4 (en) | 2019-05-10 | 2023-01-25 | Lyvgen Biopharma Holdings Limited | HUMANIZED ANTI-CD137 ANTIBODIES AND THEIR USES |
CN114127315A (zh) | 2019-05-30 | 2022-03-01 | 百时美施贵宝公司 | 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法 |
EP3976831A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
US20220233691A1 (en) | 2019-05-30 | 2022-07-28 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
JP6881658B2 (ja) | 2019-07-05 | 2021-06-02 | 小野薬品工業株式会社 | Pd−1/cd3二重特異性タンパク質による血液がん治療 |
CN114269782B (zh) | 2019-07-15 | 2023-12-29 | 上海君实生物医药科技股份有限公司 | 抗tigit抗体及其应用 |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
US20220332825A1 (en) | 2019-08-08 | 2022-10-20 | Ono Pharmaceutical Co., Ltd. | Bispecific protein |
BR112022003740A2 (pt) | 2019-08-30 | 2022-05-31 | Agenus Inc | Anticorpos anti-cd96 e métodos de uso dos mesmos |
CA3153777A1 (en) | 2019-09-22 | 2021-03-25 | Bristol-Myers Squibb Company | Quantitative spatial profiling for lag-3 antagonist therapy |
WO2021062018A1 (en) | 2019-09-25 | 2021-04-01 | Bristol-Myers Squibb Company | Composite biomarker for cancer therapy |
CN114206931A (zh) * | 2019-09-30 | 2022-03-18 | 四川科伦博泰生物医药股份有限公司 | 抗pd-1抗体及其用途 |
KR20220092578A (ko) | 2019-11-05 | 2022-07-01 | 브리스톨-마이어스 스큅 컴퍼니 | M-단백질 검정 및 이의 용도 |
WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
CA3160479A1 (en) | 2019-11-08 | 2021-05-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for melanoma |
TW202130618A (zh) | 2019-11-13 | 2021-08-16 | 美商建南德克公司 | 治療性化合物及使用方法 |
WO2021097256A1 (en) | 2019-11-14 | 2021-05-20 | Cohbar, Inc. | Cxcr4 antagonist peptides |
TW202132297A (zh) | 2019-11-22 | 2021-09-01 | 美商施萬生物製藥研發Ip有限責任公司 | 經取代吡啶及使用方法 |
CN115243721A (zh) | 2019-12-19 | 2022-10-25 | 百时美施贵宝公司 | Dgk抑制剂和检查点拮抗剂的组合 |
AU2021213969A1 (en) | 2020-01-30 | 2022-09-01 | ONA Therapeutics S.L. | Combination therapy for treatment of cancer and cancer metastasis |
KR20220136378A (ko) | 2020-01-31 | 2022-10-07 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 rna 백신을 이용하여 네오에피토프-특이적 t 세포를 유도하는 방법 |
JP2023514152A (ja) | 2020-02-06 | 2023-04-05 | ブリストル-マイヤーズ スクイブ カンパニー | Il-10およびその使用 |
CN113244385A (zh) * | 2020-02-07 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗恶性肿瘤中的用途 |
CN113248612A (zh) * | 2020-02-13 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗神经内分泌瘤中的用途 |
CN113244386A (zh) * | 2020-02-13 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在***中的用途 |
US20230235073A1 (en) | 2020-03-06 | 2023-07-27 | Ona Therapeutics, S.L. | Anti-cd36 antibodies and their use to treat cancer |
TW202143969A (zh) * | 2020-03-09 | 2021-12-01 | 大陸商和記黃埔醫藥(上海)有限公司 | 抗pd-1抗體和多受體酪胺酸激酶抑制劑的藥物組合及其使用方法 |
PE20230821A1 (es) | 2020-03-23 | 2023-05-19 | Bristol Myers Squibb Co | Anticuerpos anti-ccr8 para el tratamiento del cancer |
TW202204339A (zh) | 2020-03-31 | 2022-02-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 經取代的嘧啶及使用方法 |
TW202214623A (zh) | 2020-06-10 | 2022-04-16 | 美商施萬生物製藥研發 Ip有限責任公司 | 結晶型alk5抑制劑及其用途 |
KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
TW202204418A (zh) * | 2020-07-16 | 2022-02-01 | 大陸商和鉑醫藥(上海)有限責任公司 | Pd-1抗原結合蛋白及其應用 |
US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
CN116209466A (zh) | 2020-08-27 | 2023-06-02 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗鼻咽癌中的用途 |
US20230322930A1 (en) * | 2020-08-28 | 2023-10-12 | Shanghai Junshi Biosciences Co., Ltd. | Use of an anti-pd-1 antibody and a cytotoxic anticancer drug in treatment of non-small cell lung cancer |
JP2023540255A (ja) | 2020-08-28 | 2023-09-22 | ブリストル-マイヤーズ スクイブ カンパニー | 肝細胞癌のためのlag-3アンタゴニスト療法 |
CN116348599A (zh) * | 2020-08-31 | 2023-06-27 | 博奥信生物技术(南京)有限公司 | Pd-1结合抗体及其用途 |
WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
CN116323658A (zh) * | 2020-09-28 | 2023-06-23 | 上海君实生物医药科技股份有限公司 | 靶向PD-1或PD-L1和TGF-β的双功能蛋白及其医药用途 |
US20230374064A1 (en) | 2020-10-05 | 2023-11-23 | Bristol-Myers Squibb Company | Methods for concentrating proteins |
CN112159476B (zh) * | 2020-10-10 | 2022-08-02 | 中国药科大学 | 一种用于多发性骨髓瘤的双特异性抗体及其应用 |
AR123855A1 (es) | 2020-10-20 | 2023-01-18 | Genentech Inc | Anticuerpos anti-mertk conjugados con peg y métodos de uso |
CA3196496A1 (en) | 2020-10-23 | 2022-04-28 | Laurence David TOMS | Lag-3 antagonist therapy for lung cancer |
WO2022093981A1 (en) | 2020-10-28 | 2022-05-05 | Genentech, Inc. | Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists |
WO2022094567A1 (en) | 2020-10-28 | 2022-05-05 | Ikena Oncology, Inc. | Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine |
CA3196076A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies |
IL302396A (en) | 2020-11-04 | 2023-06-01 | Genentech Inc | Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies |
IL302217A (en) | 2020-11-04 | 2023-06-01 | Genentech Inc | Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies and anti-CD79B drug antibody conjugates |
JP2023549581A (ja) | 2020-11-17 | 2023-11-27 | シージェン インコーポレイテッド | ツカチニブ及び抗pd-1/抗pd-l1抗体の組み合わせによりがんを治療する方法 |
IL303256A (en) | 2020-12-02 | 2023-07-01 | Genentech Inc | Methods and compositions for the treatment of neoadjuvant and adjuvant carcinoma of the urinary tract |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
IL303648A (en) | 2020-12-28 | 2023-08-01 | Bristol Myers Squibb Co | Antibody preparations and methods of using them |
TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
KR20240005700A (ko) | 2021-03-29 | 2024-01-12 | 주노 쎄러퓨티크스 인코퍼레이티드 | 체크포인트 억제제 요법 및 car t 세포 요법의 조합을 사용한 투여 및 치료 방법 |
CN113087796B (zh) * | 2021-04-02 | 2022-03-18 | 河南省肿瘤医院 | 一种抗pd-l1抗体及其应用 |
EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
CN115227812A (zh) * | 2021-04-22 | 2022-10-25 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体联合一线化疗治疗晚期nsclc的用途 |
KR20240005691A (ko) | 2021-04-30 | 2024-01-12 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약 |
JP2024516230A (ja) | 2021-04-30 | 2024-04-12 | ジェネンテック, インコーポレイテッド | がんのための治療及び診断方法並びに組成物 |
CN115364208A (zh) * | 2021-05-17 | 2022-11-22 | 上海君实生物医药科技股份有限公司 | 治疗完全切除黏膜黑色素瘤的患者的药物及方法 |
WO2022242738A1 (en) * | 2021-05-20 | 2022-11-24 | Shanghai Junshi Biosciences Co., Ltd. | Use of anti-pd-1 antibody in combination with chemotherapy in treating esophageal cancer |
WO2022251359A1 (en) | 2021-05-26 | 2022-12-01 | Theravance Biopharma R&D Ip, Llc | Bicyclic inhibitors of alk5 and methods of use |
GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
CA3223534A1 (en) | 2021-07-02 | 2023-01-05 | Genentech, Inc. | Methods and compositions for treating cancer |
KR20240046323A (ko) | 2021-07-13 | 2024-04-08 | 비온테크 에스이 | 암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제 |
KR20240038008A (ko) | 2021-07-28 | 2024-03-22 | 에프. 호프만-라 로슈 아게 | 암 치료 방법 및 조성물 |
WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
CN116019907A (zh) * | 2021-07-29 | 2023-04-28 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体药物组合物及其用途 |
IL309934A (en) | 2021-07-30 | 2024-03-01 | Ona Therapeutics S L | Anti-CD36 antibodies and their use for cancer treatment |
TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法 |
WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
CA3234647A1 (en) | 2021-10-06 | 2023-04-13 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination therapy |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
WO2023077090A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
WO2023080900A1 (en) | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
WO2023097195A1 (en) | 2021-11-24 | 2023-06-01 | Genentech, Inc. | Therapeutic indazole compounds and methods of use in the treatment of cancer |
WO2023097194A2 (en) | 2021-11-24 | 2023-06-01 | Genentech, Inc. | Therapeutic compounds and methods of use |
WO2023147371A1 (en) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Combination therapy for hepatocellular carcinoma |
WO2023164638A1 (en) | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | Combination therapy for colorectal carcinoma |
WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023196987A1 (en) | 2022-04-07 | 2023-10-12 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2023196964A1 (en) | 2022-04-08 | 2023-10-12 | Bristol-Myers Squibb Company | Machine learning identification, classification, and quantification of tertiary lymphoid structures |
WO2023219613A1 (en) | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023218046A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020432A1 (en) | 2022-07-19 | 2024-01-25 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
EP4310197A1 (en) | 2022-07-21 | 2024-01-24 | Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda | Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy |
WO2024049949A1 (en) | 2022-09-01 | 2024-03-07 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
WO2024069009A1 (en) | 2022-09-30 | 2024-04-04 | Alentis Therapeutics Ag | Treatment of drug-resistant hepatocellular carcinoma |
WO2024077095A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating bladder cancer |
WO2024077166A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating lung cancer |
WO2024091991A1 (en) | 2022-10-25 | 2024-05-02 | Genentech, Inc. | Therapeutic and diagnostic methods for multiple myeloma |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2166368T3 (es) * | 1993-12-24 | 2002-04-16 | Merck Patent Gmbh | Inmunoconjugados. |
CN1359937A (zh) * | 2000-12-20 | 2002-07-24 | 上海博德基因开发有限公司 | 一种新的多肽——人细胞程序性死亡因子Mch11.11和编码这种多肽的多核苷酸 |
EP3287144A1 (en) | 2002-07-03 | 2018-02-28 | ONO Pharmaceutical Co., Ltd. | Immunopotentiating compositions |
CA2970873C (en) * | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
JP5406019B2 (ja) * | 2006-05-17 | 2014-02-05 | セルーメン、インコーポレイテッド | 自動化組織分析のための方法 |
AU2007268591A1 (en) | 2006-05-31 | 2007-12-06 | Astellas Pharma Inc. | Humanized anti-human osteopontin antibody |
EP3222634A1 (en) * | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
US9243052B2 (en) * | 2007-08-17 | 2016-01-26 | Daniel Olive | Method for treating and diagnosing hematologic malignancies |
EP2262837A4 (en) * | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
CA2736829C (en) * | 2008-09-12 | 2018-02-27 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
AU2009296392B2 (en) * | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
KR101050829B1 (ko) * | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제 |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
CA2791930A1 (en) * | 2010-03-11 | 2011-09-15 | Kerry Louise Tyson | Pd-1 antibody |
CN102298053B (zh) * | 2011-05-20 | 2014-01-29 | 中山大学肿瘤防治中心 | 原发性肝细胞肝癌术后复发风险评估的组合抗体试剂盒 |
CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
-
2013
- 2013-06-26 CN CN201310258289.2A patent/CN104250302B/zh active Active
-
2014
- 2014-02-26 EP EP14818708.1A patent/EP3026062B1/en active Active
- 2014-02-26 BR BR112015031883-5A patent/BR112015031883A2/pt not_active Application Discontinuation
- 2014-02-26 JP JP2016522196A patent/JP6681327B2/ja active Active
- 2014-02-26 PT PT148187081T patent/PT3026062T/pt unknown
- 2014-02-26 US US14/392,360 patent/US10066013B2/en active Active
- 2014-02-26 DK DK14818708.1T patent/DK3026062T3/da active
- 2014-02-26 PL PL14818708T patent/PL3026062T3/pl unknown
- 2014-02-26 HU HUE14818708A patent/HUE052487T2/hu unknown
- 2014-02-26 ES ES14818708T patent/ES2822927T3/es active Active
- 2014-02-26 EP EP20189272.6A patent/EP3845562A1/en active Pending
- 2014-02-26 RU RU2016102176A patent/RU2663795C2/ru active
- 2014-02-26 MY MYPI2015704733A patent/MY176822A/en unknown
- 2014-02-26 SI SI201431678T patent/SI3026062T1/sl unknown
- 2014-02-26 WO PCT/CN2014/072574 patent/WO2014206107A1/zh active Application Filing
-
2015
- 2015-12-18 PH PH12015502819A patent/PH12015502819A1/en unknown
-
2018
- 2018-07-25 US US16/045,363 patent/US10815302B2/en active Active
-
2020
- 2020-09-16 US US17/022,719 patent/US20210009688A1/en active Pending
- 2020-10-07 HR HRP20201600TT patent/HRP20201600T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
DK3026062T3 (da) | 2020-10-12 |
EP3026062B1 (en) | 2020-08-05 |
HUE052487T2 (hu) | 2021-05-28 |
JP2016523265A (ja) | 2016-08-08 |
MY176822A (en) | 2020-08-24 |
ES2822927T3 (es) | 2021-05-05 |
US20160272708A1 (en) | 2016-09-22 |
PH12015502819A1 (en) | 2016-03-21 |
EP3026062A4 (en) | 2017-08-16 |
JP6681327B2 (ja) | 2020-04-15 |
EP3845562A1 (en) | 2021-07-07 |
EP3026062A1 (en) | 2016-06-01 |
PL3026062T3 (pl) | 2021-01-11 |
PT3026062T (pt) | 2020-10-13 |
SI3026062T1 (sl) | 2020-12-31 |
US10815302B2 (en) | 2020-10-27 |
US10066013B2 (en) | 2018-09-04 |
US20210009688A1 (en) | 2021-01-14 |
US20190023782A1 (en) | 2019-01-24 |
RU2016102176A (ru) | 2017-07-31 |
BR112015031883A2 (pt) | 2018-02-14 |
CN104250302A (zh) | 2014-12-31 |
RU2663795C2 (ru) | 2018-08-09 |
WO2014206107A1 (zh) | 2014-12-31 |
CN104250302B (zh) | 2017-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201600T1 (hr) | Anti-pd-1 antitijelo i njegova uporaba | |
HRP20201852T1 (hr) | Optimizacija antitijela koja vezuju limfocitni aktivacijski gen-3 (lag-3), i njihove primjene | |
HRP20211594T1 (hr) | Anti-pd1 protutijela i načini uporabe | |
CO2018013500A2 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
HRP20210372T1 (hr) | Anti-lag3 antitijela i antigen-vezujući fragmenti | |
HRP20211794T1 (hr) | Humana antitijela za pd-1 | |
BR112016029916A2 (pt) | inibidores mnk e métodos correlatos | |
PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
PE20170953A1 (es) | ANTICUERPOS ANTI-CD79b Y METODOS DE USO | |
RU2017119543A (ru) | Анти-tim3 антитела и способы их применения | |
EA201890530A1 (ru) | Конъюгаты антитела к dll3 и лекарственного средства и способы их применения | |
EA201400625A1 (ru) | Антитела против pd-l1 и их применение | |
WO2015187596A3 (en) | Antibody-drug conjugates, their preparation and their therapeutic use | |
UA111386C2 (uk) | Піридопіразини, які мають протиракову активність через інгібування fgfr-кіназ | |
WO2015012904A3 (en) | Antibody-sn-38 immunoconjugates with a cl2a linker | |
UY36404A (es) | ANTICUERPOS MONOCLONALES (Ab) COMO DETECTORES DE CD73 E INHIBIDORES DE SU ACTIVIDAD ENZIMÁTICA, Y COMPOSICIONES QUE LOS CONTIENEN | |
AR091702A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
AR098743A1 (es) | Anticuerpos e inmunoconjugados anti-cd33 | |
BR112015006341A2 (pt) | compostos, composição farmacêutica, método para tratar condição fibrótica, quantidade terapeuticamente efetiva de composto, de sal farmaceuticamente aceitável deste ou de composição farmacêutica e usos das mesmas e de compostos e/ou composição farmacêutica | |
PE20141560A1 (es) | Anticuerpo anti-epirregulina humanizado y agente terapeutico contra el cancer que comprende dicho anticuerpo como ingrediente activo | |
EA201691251A1 (ru) | Цитотоксические пептиды и их конъюгаты | |
AR091701A1 (es) | Anticuerpos anti-cd22 e inmunoconjugados | |
TR201900057T4 (tr) | Selektif histon deasetilaz (HDAC) inhibitörleri olarak yeni azaindol deriveleri ve bunları içeren farmasötik bileşimler. | |
BR112015032713A2 (pt) | composto; composição terapêutica; composição farmacêutica; método para tratar o câncer em um paciente em necessidade; e método para induzir anticorpos em um animal ou um humano para a finalidade de criar anticorpos monoclonais para usos terapêuticos ou diagnósticos |